Obesity is a complex, heritable disorder and a worldwide epidemic, yet historically, gene discoveries related to this condition have predominantly relied on studies of homogeneous populations, particularly those of European ancestry. This ancestral bias limits the generalizability of findings and hampers the development of effective precision medicine approaches globally. Fortunately, a massive new study, led by researchers at Penn State and published in Nature Communications , has successfully tackled this limitation by employing a cross-ancestry analysis . The study examined the genetic data and BMI of 839,110 individuals from six continental ancestries (African, American, East Asian, European, Middle Eastern, and South Asian). Data were leveraged from two significant resources: the UK Biobank (UKB) and the more diverse All of Us (AoU) Research Program. By focusing on rare, high-impact predicted loss-of-function variants, the researchers identified 13 genes significantly associated with Body Mass Index (BMI). Crucially, five of these genes had not been previously linked to obesity in prior rare-variant studies. These novel obesity genes  are YLPM1 , RIF1 , GIGYF1 , SLC5A3 , and GRM7 . The impact of these newly discovered genes is substantial: four of them— YLPM1 , RIF1 , GIGYF1 , and GRM7 —were found to confer about a three-fold risk for severe obesity. Their effect sizes were comparable to established obesity genes like MC4R  and BSN . Like many known obesity genes, the new discoveries are expressed in the brain and adipose tissue, reinforcing the central role of the central nervous system (CNS) in weight homeostasis. The analysis provided critical insights into how genetic risk operates across different populations. Genes such as YLPM1 , MC4R , and SLTM  showed remarkably consistent effects on BMI across multiple ancestries, highlighting their generalizability. However, others, like GRM7  and APBA1 , exhibited significant ancestral heterogeneity or European-specific bias, underscoring why studies lacking genetic diversity  often miss important global drivers of disease. Furthermore, the researchers explored the downstream health consequences, finding that these genes also influence cardiometabolic comorbidities. For example, GIGYF1  and SLTM  carriers showed increased risk for Type 2 Diabetes, partially mediated by BMI. In contrast, SLC5A3  showed a significant direct link to gastroesophageal reflux disease (GERD) independent of BMI. The findings also confirm that polygenic risk, stemming from common variants, acts additively alongside rare, high-impact variants to increase obesity penetrance. This comprehensive view of obesity genetics, obtained by prioritizing genetic diversity  through cross-ancestry analysis , provides indispensable insights that will guide effective therapies and precision medicine globally. 🔖 Sources Massive cross-ancestry study explains why obesity risks differ around the world Discovery of obesity genes through cross-ancestry analysis Scientists discover five new genes which increase obesity risk Discovery of novel obesity genes through cross-ancestry analysis

The political standoff that has plunged the U.S. federal government into a shutdown, now deep into its 28th day, centers crucially on a fight over American healthcare costs. Democrats have drawn a firm line: they are demanding Republicans agree to extend subsidies for the Affordable Care Act (ACA) set to expire this Saturday before they will vote to end the Government Shutdown . This dispute has put the nation’s healthcare system squarely at center stage. Without congressional action to extend these enhanced Obamacare Subsidies —first implemented during the COVID-19 pandemic—the consequences for millions of Americans will be immediate and severe. Health insurance premiums are expected to more than double  for approximately 20 million people who receive their coverage through the ACA. Many individuals have already faced "sticker shock" upon receiving letters detailing their drastically increased new premiums, with some reports indicating potential hikes of up to 30%. Public awareness of these anticipated price increases highlights a major surge in health insurance costs. The refusal to extend these vital tax credits is seen by critics as part of a larger trend favoring profit over public good in healthcare. Dr. Steffie Woolhandler, a physician and distinguished professor of public health at Hunter College-CUNY and co-founder of Physicians for a National Health Program, notes that the purpose of healthcare has increasingly become profit-making rather than a public service . According to Dr. Woolhandler, while extending the Obamacare Subsidies  is "vital", the ultimate goal must be to move toward universal public healthcare, mirroring every other major Western economy, and away from the current private, profit-oriented system. The current administration and Republican Congress are also accelerating price increases through other measures. The administration signed the "One Big Beautiful Bill," slated to cut $1 trillion  from the Medicaid program. Since more than one in five Americans rely on Medicaid, and the program is a major source of funding for most community and rural hospitals, these cuts will ultimately affect the quality of healthcare for everyone, not just the poorest citizens. The cuts also reduce subsidies for medications for many people on Medicare. Furthermore, the administration has given "giveaways" to private insurance companies involved in Medicare Advantage, doubling their pay increase this year. This occurred despite an official congressional Medicare Payment Advisory Commission concluding that these private companies are already being overpaid by about $80 billion annually . Dr. Woolhandler criticized Medicare Advantage as a "giant waste of money," which has raised costs for taxpayers by $80 billion in the past year alone and over $600 billion in the past two decades. This practice also contributes to increasing costs for Medicare beneficiaries through higher Part B premiums. When compared globally, the U.S. private system yields healthcare costs more than 50% higher than those in other developed nations. Yet, Americans have significantly worse health outcomes, with the average U.S. life expectancy being four years shorter than in countries like Canada, France, or Holland. This context reinforces the argument that the enduring solution lies in single-payer "Medicare for All," a vision that healthcare advocates are striving to realize, keeping their "eye on the prize" amid the ongoing political crisis. 🔖 Sources U.S. healthcare system pushed into spotlight as fight over subsidies continue Obamacare Premiums Could Jump 30% as Subsidies Expire Obamacare Prices Become Public, Highlighting Big Increases Millions Face Soaring Health Insurance Premiums as GOP Refuses to Extend Obamacare Subsidies

Image credit: NBC / Chicago Med . Fair use. The medical procedural genre thrives on high stakes and evolving characters, and the One Chicago universe is no exception. The halls of Gaffney Chicago Medical Center welcomed a highly recognizable face to its ranks in Chicago Med  Season 11, Episode 4, "Found Family," with the debut of actor Manish Dayal . Known primarily for his extensive tenure in medical dramas, Dayal steps into the role of Dr. Theo Rabari , a bright-eyed psychiatrist whose innovative, research-focused approach is set to shake up the established dynamics, particularly within the psychiatric department led by Dr. Daniel Charles (Oliver Platt). This guest role marks Dayal’s exciting return to the medical procedural world two years after his previous series concluded. For viewers who love medical dramas, Dayal’s appearance was instantly familiar. His transition into the One Chicago universe as Dr. Theo Rabari creates an exciting chapter for Chicago Med  and promises new interactions among the staff. Dr. Rabari’s focus on using advanced technology for mental health diagnosis sets him on a collision course with traditional methods, raising critical questions about the future of patient care. Content ⁉️ 1️⃣ The Return of a Medical Drama Favorite 2️⃣ Dr. Theo Rabari: An Innovator Shaking Up Gaffney Psychiatry 3️⃣ The Clash of Ideologies: Dr. Rabari vs. Dr. Charles 4️⃣ Found Family and Ongoing Arcs in Season 11 🔖 Key Takeaways Image credit: Collider / Chicago Med . Fair use. The Return of a Medical Drama Favorite Manish Dayal built an impressive television and film career, boasting a "chameleonic range" across several genres, before scrubbing into Gaffney. His breakout role was Dr. Devon Pravesh in the Fox medical drama The Resident . Dayal portrayed Dr. Pravesh for the show's six-season run, during which fans watched the character evolve from a young resident to a seasoned attending physician by the show’s end. His tenure as Dr. Pravesh cemented him as a standout character and a familiar fixture in primetime medical procedurals. Dayal's professional background extends beyond the hospital setting. Following The Resident , he appeared in several episodes of the second season of The Walking Dead: Daryl Dixon , originating the role of Ash Patel, an airplane pilot and father whose path crossed with Carol. Ash was last seen escaping in a plane heading for America, leaving the door open for his potential return to that franchise. Other notable television credits include guest appearances or recurring roles in series such as CSI: Crime Scene Investigation , 90210 , Rubicon , The Good Wife , and Vijay Nadeer on Agents of S.H.I.E.L.D. . Furthermore, Dayal has appeared in big-screen projects such as The Hundred Foot Journey , Viceroy's House , and the holiday romantic comedy Holidate . Interestingly, the South Carolina-born actor, whose birth name is Manish Sudhir Patel, chose the stage name Manish Dayal as a tribute to his grandfather. He also guest starred in Dick Wolf's Law & Order  franchise on two separate occasions, appearing in Criminal Intent  in 2011 and Special Victims Unit  in 2014. Dr. Theo Rabari: An Innovator Shaking Up Gaffney Psychiatry Dr. Theo Rabari arrives at Gaffney Chicago Medical Center as a research psychiatrist. In his debut on Chicago Med , Rabari addressed a conference to pitch an innovative new diagnostic tool known as an fMRI  (functional Magnetic Resonance Imaging). Rabari aimed to replace the traditional "guessing game" associated with mental health diagnoses by providing "hard facts". His core argument was that these new MRIs would be fully impartial, preventing psychiatrists from relying on personal biases or emotions during patient assessments. He posited that utilizing such tools would increase efficiency, instantly diagnose mental disorders, and consequently push psychiatry into a more cemented science. He proposed to continue his research at the institution following the conference. Image credit: NBC / Chicago Med . Fair use. The Clash of Ideologies: Dr. Rabari vs. Dr. Charles Rabari's technologically driven approach immediately created friction with Gaffney's Head of Psychiatry, Dr. Daniel Charles (Oliver Platt). Dr. Charles, a proponent of traditional, compassionate, and human-centered psychiatric care, initially worried that Rabari’s reliance on technology would lead to a loss of personal connection between doctors and their patients. Charles was adamant that patients require human contact and compassion more than anything. The Critical Case of Lionel Despite his initial skepticism, Dr. Charles was confronted with a particularly complex case that demonstrated the potential value of Rabari’s research. A patient named Lionel was admitted after amputating his own hand. Lionel claimed he did so to prevent himself from potentially killing someone due to OCD-like compulsions, and he refused to allow the doctors to reattach his severed arm. After diagnosing Lionel with Harm OCD, Dr. Charles determined the most effective way to convince the patient to accept the reattachment surgery was to demonstrate scientifically that he was suffering from a chemical imbalance, not murderous intent. Charles realized Rabari had the perfect tools for the job and brought him in to utilize his fMRI technology on Lionel. The brain scan confirmed Charles’s suspicions. Charles then used the scan to explain to Lionel that he deserved to feel whole again and encouraged him to trust the scientific findings. Inspired by these findings, Lionel agreed to the surgery, which went well. Following the successful procedure, Rabari visited Charles's office for a follow-up. Dr. Charles acknowledged that he was not anti-innovation, but simply wary of new technological advancements that could inhibit a doctor's ability to connect personally with patients. However, he could not deny the success of Rabari's research in this critical situation. Charles ultimately told Rabari: "Look, if you were willing to put people before technology, maybe there is a place for you and your research here at Gaffney,"  and Rabari eagerly accepted the offer. This positive resolution leaves the door open for Dayal’s character to potentially return in future episodes of Chicago Med  Season 11. Image credit: TheThings / Chicago Med . Fair use. Found Family and Ongoing Arcs in Season 11 While Dr. Rabari’s introduction occupied a central theme of innovation versus traditional care, Episode 4, "Found Family," explored several other complex patient stories and developing character arcs. The episode title reflected the case of young Cora Cooper (Hattie M. Baker), a tender patient battling immunodeficiency. Dr. Frost (Darren Barnet) bonded closely with Cora, who had to stay within an isolation barrier. The search for a stem cell donor revealed that Cora's caretaker, Vivienne (Erin Davie), was not a match, but the search successfully located Billie as Cora’s biological mother and donor match. The case helped Cora reconnect with her birth mother, while Billie resolved her existing issues with Vivienne. This case also hinted at potential complexities in Dr. Frost's background, asking whether attending to Cora would unearth more complex memories or help Frost begin healing from a troubled childhood. Additionally, the episode furthered personal storylines for the main cast. Dr. Frost confided that he was facing severe financial problems and homelessness, which was affecting his behavior. Dr. Ripley stepped in to help him find accommodation. Dr. Ripley was also involved in handling a case of domestic abuse involving patient Faye, who claimed her serious belly injuries were due to an accidental kettle explosion. Despite Faye's refusal to act on her situation, Dr. Lenox (Sarah Ramos) provided treatment. Lenox was also featured in a different case involving a One Chicago cameo: Kim Burgess (Marina Squerciati) from Chicago P.D.  will join Lenox on a case, described as "a bit girl detective work". The Horizon of Chicago Med Season 11 The season continues to delve into long-running arcs, including the situation concerning Dr. Hannah (Jessy Schram) and Dr. Archer (Steven Weber). Upcoming episodes are also teased, including the Halloween-themed Episode 5. This episode is slated to be a significant case for Hannah, involving a young woman who comes in with a "pretty massive secret" that is described as heartbreaking and potentially deadly. Hannah will serve as a strong advocate for this patient, demonstrating a deeper understanding that situations are not always "black and white". 🔖 Key Takeaways The introduction of Manish Dayal  as Dr. Theo Rabari  marked a significant moment in Chicago Med Season 11 , blending technological innovation with established medical ethics. 🗝️ Familiar Face, New Role:  Dayal, recognized for his six seasons as Dr. Devon Pravesh on The Resident , smoothly transitioned into the One Chicago universe as a guest star. 🗝️ Innovation vs. Compassion:  Dr. Rabari’s debut revolved around pitching the use of fMRI technology to bring "hard facts" to psychiatric diagnoses, a move initially opposed by Dr. Charles, who valued human connection over efficiency. 🗝️ Proof of Concept:  The high-stakes case of Lionel, the patient who self-amputated his arm, provided the evidence needed to showcase the fMRI’s effectiveness in convincing the patient of his chemical imbalance, leading to successful reattachment. 🗝️ A Door Left Open:  Dr. Charles ultimately invited Dr. Rabari to continue his research at Gaffney, provided he maintained his focus on putting people before technology, suggesting Rabari may recur in future episodes. 🗝️ Season Scope:  Beyond Rabari's arrival, Season 11 explores complex personal arcs for characters like Dr. Frost (homelessness and complex patient relationships) and Dr. Hannah (complex patient advocacy), alongside promised crossover cameos like Kim Burgess from Chicago P.D. . 🌐 External sources A ‘The Resident’ Star Drops By ‘Chicago Med’ in New Season 11 Images Who is Manish Dayal? Everything to know about the actor and the new doctor in Chicago Med Here's why Dr. Theo Rabari from Chicago Med looks so familiar to you

The pharmaceutical landscape was dramatically shaken this week, culminating in a high-stakes, rapidly escalating Bidding War  that underscores just how valuable control of the Obesity Drug Market  has become. At the center of this storm is Metsera, a biotech firm whose promise has attracted intense competition between two titans: Novo Nordisk  and Pfizer . Reports surfaced on October 30, 2025, detailing Novo Nordisk’s bold move: an unsolicited proposal launched to acquire Metsera. This action effectively "hijacked" the standing offer from Pfizer , throwing the established deal into turmoil. The move is the latest twist in the ongoing competitive dynamics between these two global drug giants. The urgency surrounding the acquisition is palpable, driven by the immense financial potential embedded in weight loss medications. Novo Nordisk’s  bid was not merely a gesture; it was an offer that immediately topped Pfizer’s  standing proposal. Metsera’s leadership recognized the significance of this unsolicited advance, officially deeming the bid from Novo Nordisk to be superior to Pfizer’s terms. This decision by Metsera has put Pfizer  on the defensive, providing the company with a tight window—just four business days—to respond and potentially renegotiate its offer. Should Pfizer fail to raise its stake or match the terms set by its rival, Metsera appears prepared to move forward with the acquisition by Novo Nordisk. The reaction from Pfizer  has been sharp and critical. In response to the aggressive maneuvering, Pfizer officials reportedly characterized Novo Nordisk’s  bid as "reckless". This rhetorical battle highlights the deeply competitive nature of the transaction and the lengths both companies are willing to go to secure a leading edge in the burgeoning weight loss sector. This clash represents more than just a typical corporate acquisition; it is a fierce struggle for market dominance in what may be the defining therapeutic area of the next decade. Novo Nordisk , already a major player in this space, is demonstrating its commitment to expanding its portfolio and neutralizing potential threats. By launching a rival Metsera Bid , the company cemented the fact that no deal, regardless of how advanced, is safe from disruption in this highly contested Obesity Drug Market . As the four-day clock winds down, all eyes remain fixed on Pfizer . Whether they meet the challenge with an even higher bid or choose to let Metsera slip into the hands of their primary competitor will define not only the immediate fate of Metsera but potentially reshape the competitive landscape of pharmaceutical weight loss treatments for years to come. The outcome of this Bidding War  remains highly uncertain, but the message is clear: the fight for the future of obesity treatment is only just beginning. 🔖 Sources Novo Nordisk makes offer for obesity-focused Metsera, aiming to outbid Pfizer Novo Nordisk enters bidding war with Pfizer over US biotech Metsera Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera

The landscape of diabetes management is undergoing a revolutionary shift, driven by significant therapeutic breakthroughs  across pharmacology, technology, and cellular science. Recent reports, including insights from the European Association for the Study of Diabetes  (EASD) conference and high-profile research publications, highlight innovations aimed at not only controlling blood sugar but also preventing long-term complications  and easing the daily burden of care. One of the most promising therapeutic breakthroughs  is a new small molecule drug, RAGE406R, developed by researchers from the University at Albany and NYU Grossman School of Medicine. This compound targets a key cellular pathway responsible for chronic inflammation and impaired wound healing in people with diabetes. RAGE406R works by disrupting the connection between the RAGE receptor and DIAPH1 inside cells, thereby blocking the trigger for inflammation. This is crucial because current diabetes treatments primarily slow disease progression but do not address the underlying inflammation that drives complications. Testing in human cells and mice confirmed that RAGE406R significantly reduced inflammatory messengers and accelerated wound healing in Type 2 diabetes (T2D) mice. If confirmed in human trials, this compound could potentially fill existing treatment gaps, especially since most current inflammation-targeting drugs often only work against T2D. Pharmacological advancements continue to redefine T2D treatment. Novel glucose-lowering agents, such as dual and triple incretin agonists targeting GLP-1, GIP, and glucagon receptors (like tirzepatide and retatrutide), are showing remarkable benefits for glucose control, cardiovascular health, and weight reduction. Furthermore, an oral GLP-1 agonist, Orforglipron, has demonstrated substantial weight loss in clinical trials for people living with obesity. The availability of oral formulations is expanding access for those who prefer not to use injections. In a vital step for pediatric care, the drug Mounjaro (tirzepatide) has shown meaningful improvements in both blood sugar control and weight loss for children and young people with T2D, a population with limited effective treatment options. Technological innovation is rapidly moving toward full automation. Closed-Loop Systems , also known as Automated Insulin Delivery (AID) or artificial pancreas (AP) systems, integrate continuous glucose monitors (CGM) with insulin pumps to automate insulin delivery. While hybrid systems are already transformative for Type 1 diabetes (T1D), trials on fully Closed-Loop Systems —designed to automate all insulin delivery, including mealtime boluses—demonstrated significant benefits. In both T1D and T2D, these fully Closed-Loop Systems  allowed participants to spend several additional hours each day in their target range, accompanied by less stress, improved sleep, and reduced mental burden around meal management. The integration of CGMs, AI, and mobile health apps further revolutionizes personalized care, offering real-time data analysis and tailored treatment recommendations. Addressing the root cause of T1D, researchers shared updates on beta cell replacement therapies, including Vertex’s zimislecel, which has shown individuals coming off insulin entirely at the one-year mark. Meanwhile, experimental therapies like Anti-thymocyte Globulin (ATG) and Baricitinib continue to be investigated for their ability to delay or prevent T1D onset by preserving residual beta cell function. Finally, the emotional challenges of living with Diabetes  are receiving formalized recognition with the launch of the world’s first clinical practice guideline focused on diabetes distress. This guideline recommends that healthcare professionals routinely assess emotional coping using open-ended questions and validated tools, marking an important step toward holistic, patient-centered care. 🔖 Sources Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications Editor’s Pick: Treatment of Type 2 Diabetes: A Comprehensive Review of Recent Improvements, Therapeutic Strategies, Challenges, and Future Perspectives Exciting research updates shared at the 2025 European Association for the Study of Diabetes (EASD) Meeting Diabetes distress guideline and fully closed loop benefits: Research highlights September 2025

Image credit: MSN / Best Medicine . Fair use. Fox is set to launch a highly anticipated new medical comedy-drama titled Best Medicine , an adaptation of the immensely popular British series Doc Martin . After running for 10 seasons across 18 years for British broadcaster ITV, the original Doc Martin  established itself as a global hit centered on the life of a brilliant, but socially inept, doctor. Fox is keen to capture the format’s success, viewing Best Medicine  as an opportunity to expand its audience through comedy, particularly a one-hour comedy format which the network hasn't pursued in almost a decade. The adaptation is generating immense buzz, not just for bringing the "flawed, no filter character" and the "aspirational small town setting" to US television, but for securing the participation of the original star, Martin Clunes , who played the title character in the UK version. Content ⁉️ 1️⃣ The Enduring Charm of the Abrasive Physician 2️⃣ Best Medicine: A Signature Fox One-Hour Comedy 3️⃣ The Martin Clunes Twist: Father Knows Worst 4️⃣ A Gallery of Quirky Locals: The Ensemble Cast 5️⃣ The Future of the Medical Comedy-Drama 🔖 Key Takeaways Image credit: Cornwall Live / Best Medicine . Fair use. The Enduring Charm of the Abrasive Physician The core concept that made Doc Martin  a masterpiece—and what makes Best Medicine  so compelling—is the contrast between clinical brilliance and social awkwardness. The American adaptation follows Dr. Martin Best  (played by Josh Charles), a brilliant surgeon who abruptly abandons his illustrious career in Boston. Seeking a change of pace, he becomes the general practitioner in a quaint East Coast fishing village where he spent summers as a child. The Original Phenomenon The original Doc Martin  aired from 2004 to 2022 and was created by Dominic Minghella. The series successfully navigated the fine line of showcasing a character who is "gruff, anti-social, and stern" yet still somehow manages to be "respected and beloved by your community". Fox executives loved the original format for its mixture of "humor, charm, optimism, and edge". Dr. Martin Best carries this legacy forward; unfortunately for him and the locals, his bedside manner is described as blunt and borderline rude , quickly alienating the quirky, needy residents, even though he is "all they’ve got". Best Medicine: A Signature Fox One-Hour Comedy The decision by Fox to invest in Best Medicine  reflects a deliberate strategy to broaden their definition of comedy beyond the traditional half-hour live-action format. Michael Thorn, President of Fox Television Network, expressed enthusiasm for the adaptation, noting that the combination of the messy lead character and the wonderful, quirky ensemble of supporting characters works perfectly for the network’s audience. Liz Tuccillo, who is adapting the American version, has been praised for capturing the elements that made the British original a proven global hit. The series is currently filming in upstate New York and is slated to premiere during the 2025–26 TV season. Image credit: TheWrap / Best Medicine . Fair use. The Martin Clunes Twist: Father Knows Worst The most exciting development for fans of the original series is the casting of Martin Clunes , the former titular star, in a new, pivotal role. Clunes, who portrayed Doc Martin  for nearly two decades, is joining the US remake as Dr. Robert Best, the father of the American lead, Martin Best. This casting choice adds a layer of intergenerational conflict that promises deep dramatic and comedic potential. Martin Clunes’ Return: A Twist of Fate Clunes’ character, Dr. Robert Best , is an accomplished, headstrong gastroenterologist. Crucially, his personality is described as being so abrasive that he makes his already prickly son, Martin, look "practically cozy by comparison". Robert Best is estranged from his sister, Aunt Joan (Sarah), who is played by Annie Potts. His surprise arrival in the East Coast fishing village puts everyone on edge, and underneath his snobby, stone-cold exterior, he is "hiding a few secrets of his own that could turn Martin’s new life upside down and force him to confront his past". The age difference between Clunes (the father) and Josh Charles (the son) is only nine years in real life, making the dynamic intriguing. Image credit: Us Weekly / Best Medicine . Fair use. A Gallery of Quirky Locals: The Ensemble Cast Just as the original relied on the colorful residents of Portwenn, Best Medicine  is building a strong ensemble to challenge and complicate Dr. Best’s life. These supporting players provide the necessary warmth and humor to balance Martin’s cynical demeanor. The cast includes Abigail Spencer  as Louisa Glasson, a local school teacher who immediately clashes with Martin but is simultaneously intrigued by him. This mirrors the central romantic tension of the original series. Adding complication to this budding relationship is Josh Segarra  as Sheriff Mark Mylow, a charming lawman still recovering from a recent breakup with Louisa, thus forming a bit of a love triangle. Another key local is Aunt Joan  (Annie Potts), characterized as a strong, sturdy lobster woman who is "salt of the earth". Despite her stern exterior, she has a large heart and loves her cranky nephew. She is loyal yet stubborn and, notably, holds a few secrets regarding why she and Martin lost touch many years ago, adding depth to the familial dynamic. Furthermore, Cree  plays Elaine Denton, who works at the practice but is charmingly inept and more focused on becoming a YouTube star. The large cast also includes Didi Conn  (Councilwoman Geneva Potter), Clea Lewis  (Pharmacist Sally Mylow), and the proprietors of The Salty Breeze, among others. The Future of the Medical Comedy-Drama Best Medicine  is set to deliver a unique blend of high-stakes medical drama and small-town character comedy that, according to Fox, is unlike anything currently on broadcast TV. The involvement of original Doc Martin  executive producers Mark Crowdy and Philippa Braithwaite alongside Liz Tuccillo further solidifies the show’s connection to the British success, offering reassurance to long-time fans. While some fans of the original are approaching the remake with "cautionary reserve," expressing hope that it avoids gimmicks like a laugh track, the overwhelming sentiment is excitement, particularly concerning Clunes’ surprise return. The anticipation for the 2025–26 premiere suggests that the diagnosis for Fox’s new prescription is overwhelmingly positive. 🔖 Key Takeaways 🗝️ Best Medicine   is the US adaptation of the beloved UK series   Doc Martin , a medical comedy-drama that ran for 10 seasons. 🗝️ The series centers on Dr. Martin Best (Josh Charles) , a brilliant former Boston surgeon whose abrasive bedside manner creates conflict in the quaint East Coast fishing village where he becomes the general practitioner. 🗝️ Original Doc Martin  star Martin Clunes  joins the cast as Dr. Robert Best , Martin’s father. Robert is a headstrong gastroenterologist with an even more abrasive demeanor than his son and is hiding crucial secrets. 🗝️ The ensemble cast, which includes Abigail Spencer  (Louisa Glasson), Josh Segarra  (Sheriff Mark Mylow), and Annie Potts  (Aunt Joan), provides the "quirky" small-town setting and romantic tension essential to the format. 🗝️ Best Medicine   is a key strategic launch for Fox , marking its return to the one-hour comedy-drama format. 🌐 External sources Everything to Know About Fox’s New Medical Series ‘Best Medicine’: ‘Doc Martin’ Connection, More Fox’s ‘Best Medicine’ Adds ‘Doc Martin’ Star in Guest Role ‘Doc Martin’s Martin Clunes Joins Fox’s U.S. Remake ‘Best Medicine’

The challenge of delayed hospital discharges is a persistent issue facing U.S. hospitals, often leading to insufficient bed capacity and slow patient throughput. However, recent studies suggest a powerful, repeatable solution: the implementation of Standardized Discharge Criteria . This approach, moving away from arbitrary individual physician decisions, is proving to be a game-changer for Hospital Efficiency . A comprehensive pilot study conducted by UCLA Health, published in BMJ Open Quality , offers compelling evidence of the system's success. The 18-month discharge improvement test focused on four common neurological and medical conditions: syncope (fainting), transient ischemic stroke, seizures, and demyelinating diseases. Researchers utilized input from all involved stakeholders—from patient admission through to discharge—to create a unified, consensus-based set of criteria for when a patient was truly ready to go home. The results were immediate and sustained, offering a clear template for other institutions. The standardization effort achieved a nearly 50% reduction in the median time patients spent waiting to leave the hospital after discharge orders were placed. Specifically, median time from discharge order to actual discharge plummeted 49%, dropping from 171 minutes to 88 minutes. Crucially, these improvements persisted for six months after implementation, with median discharge times remaining stable at 92 minutes. In fact, the shift meant that more than 80% of patients were discharged within two hours of their orders being placed. This drastic improvement in flow led directly to a significant Reduced Length of Stay  (LOS). The overall median hospital stays decreased by 2.5 days, showcasing the enhanced Hospital Efficiency . Further demonstrating the power of standardization, a separate study focused on enhancing patient flow reported a similar effect, showing a decrease in LOS from 94 hours down to 30-35 hours. Dr. Melissa Reider-Demer, the study's lead author and a UCLA Health DNP, explained the fundamental shift in approach: "We replaced arbitrary, physician-specific discharge decisions with consensus-based criteria developed by neurology and medicine specialists". This change mitigates delays caused by variable provider preferences and empowers the entire care team—including case managers, nurses, pharmacists, and transport staff—to predict and coordinate discharges far more efficiently. The move toward consensus-based discharge has been previously recommended by the Institute for Healthcare Improvement. Although the specific criteria must be tailored to individual hospitals, the UCLA Health framework provides a valuable case study that can be adapted by other hospitals for diverse health conditions and departments. With hospital readmission rates remaining low (approximately 1.5% in the emergency room) following the change, the data strongly supports the idea that Standardized Discharge Criteria  are not just faster, but also safe and effective, offering a viable solution for the national challenge of throughput and capacity. 🔖 Sources Standardized criteria show sustained reduction in hospital stay Study finds new system can cut patient waiting times for discharge Enhancing patient flow through standardised discharge pathways for neurology and medicine services Delayed discharges from hospital

In the high-stakes environment of emergency medicine, where every second counts, the electrocardiogram (ECG) remains the cornerstone for diagnosing acute heart conditions. However, human interpretation can be challenging, particularly when dealing with severe heart attacks that present atypically. Recent findings suggest a major shift is underway, as artificial intelligence (AI) is proving itself to be not just a helpful tool, but a superior interpreter in the critical triage setting. A novel AI ECG model designed for acute Coronary Occlusion  myocardial infarction (MI) has shown immense promise in recent international evaluations. This technology is specifically demonstrating its ability to better detect severe heart attacks in the emergency setting compared to traditional methods. The key takeaway from analyses published this autumn is stark: the AI ECG  model substantially outperforms standard triage procedures when identifying acute coronary occlusion (ACO). Standard triage protocols often struggle when patients present with atypical ECG patterns, leading potentially to missed diagnoses of severe heart attacks. The new AI-driven approach overcomes these limitations, offering improved detection even in these challenging cases. In practical terms, the model has been shown to detect more confirmed STEMIs (ST-elevation myocardial infarctions—a type of severe heart attack often associated with ACO) than existing standard triage methods. This improvement in detection accuracy directly translates to better outcomes for patients, ensuring those experiencing the most critical blockages receive immediate care. Beyond simply identifying more true positives, the implementation of AI ECG triage is providing a significant lift to emergency cardiology by refining efficiency. Digital Watch reports that AI-read ECGs are contributing to better heart attack detection while simultaneously achieving a crucial goal: reducing unnecessary activations across PCI centers. Unnecessary activations, or 'false alarms,' consume valuable resources and time, and the AI model’s ability to minimize these occurrences while enhancing accuracy makes it a powerful addition to the clinical workflow. The introduction of this technology, described as a "Novel artificial intelligence model using electrocardiogram for acute coronary occlusion myocardial infarction," marks a significant step forward in diagnostic cardiology. Moving beyond mere automation, this specialized AI model provides a level of diagnostic acuity that improves upon established protocols. This ensures that emergency departments can more reliably and rapidly identify patients needing urgent intervention for acute Coronary Occlusion , regardless of how unusual their electrical tracing may appear. The implications are clear: as AI tools continue to mature, models like the AI ECG  are set to redefine triage standards, making emergency detection of severe heart attacks faster, more accurate, and more efficient globally. 🔖 Sources Novel AI ECG model outperforms standard triage for acute coronary occlusion AI ECG Better Detects Severe Heart Attacks in Emergency Setting Emergency cardiology gets a lift from AI-read ECGs, with fewer false activations Novel artificial intelligence model using electrocardiogram for detecting acute myocardial infarction needing revascularization

Image credit: BBC / Casualty . Fair use. The medical drama Casualty  is undergoing a period of intense change, both on-screen and off. Following the dramatic conclusion of the Supply and Demand  boxset, the BBC series is currently off air, leaving fans in suspense over multiple cliffhangers. Recent updates confirm not only a revised schedule for the show’s return but also monumental shifts in its foundation and setting, promising an "unprecedented" new era for the long-running drama. The narrative conclusion of the latest chapter left the fictional Holby ED team—and the viewers—in a state of shock. While the staff wait to hear the fate of a beloved colleague, the BBC is preparing for a strategic overhaul that will reshape the very geography of the series. These developments mean that when Casualty  finally returns, it will usher in a new landscape, new storylines, and a new location that seeks to sustain the show for another forty years. Content ⁉️ 1️⃣ The Delayed Casualty Return Date and the Learning Curve Ahead 2️⃣ Ngozi Okoye and Dylan Keogh: The Aftermath 3️⃣ Behind the Scenes: A New Era for Casualty 4️⃣ Beyond Ngozi: Unresolved Relationships and Lingering Threats 5️⃣ A Focus on Character and Crisis 🔖 Key Takeaways Image credit: The Sun / Casualty . Fair use. The Delayed Casualty Return Date and the Learning Curve Ahead Initially, the show was anticipated to return to screens by the end of 2025. However, a disappointing update revealed that fans will need to wait longer. Casualty  is now expected to return on January 10 . This delayed return follows the standard Christmas and New Year television viewing schedules. The show will pick up with a new mini-series titled Learning Curve , which will dive straight into the drama surrounding the cliffhanger that closed the Supply and Demand  boxset on September 20. The return is highly anticipated, with promises of "brave rescues, heartbreak, violence and new additions to the cast". The Shocking Cliffhanger of Supply and Demand The climax of Supply and Demand  centered heavily on nurse Ngozi Okoye (Adesuwa Oni) and junior doctor Nicole Piper (Sammy T Dobson). Ngozi had reluctantly decided to leave her life at Holby City Hospital to return to Lagos after her young son, Obi, expressed unhappiness in England. Nicole, realizing she wanted to be with Ngozi, raced across town with Siobhan McKenzie (Melanie Hill) to the airport to stop her departure. Unfortunately, Nicole was met with devastation. Ngozi, who is an alcoholic, had relapsed while waiting at the airport, choosing to hide in the toilets to try and miss her flight. She collapsed, hitting her head. Nicole found her son, Obi, alone before discovering Ngozi and having her rushed back to the ED. The last installment ended as the team desperately continued CPR on Ngozi, leaving her fate hanging precariously in the balance. Ngozi Okoye and Dylan Keogh: The Aftermath The first order of business for the new mini-series Learning Curve  will be to resolve Ngozi’s fate—specifically, determining if she survived her fall and the subsequent rush to the hospital. This tragic event is set to put a significant strain on senior consultant Dylan Keogh (William Beck), who had acted as Ngozi’s sponsor throughout her storyline. Dylan looks set to be at the center of the drama upon the show’s return. Actor Will Beck noted that if Ngozi does not pull through, Dylan will be determined to get to the bottom of what went wrong. Dylan’s reaction will be a measure of how well he has adjusted to his own personal struggles, and he will need to reach out for support. The show’s return will see Dylan tested like never before, even as far back as the Public Property  boxset where he faced police questioning regarding a patient’s death. Image credit: News Shopper / Casualty . Fair use. Behind the Scenes: A New Era for Casualty While the on-screen drama unfolds, the production of Casualty  is undergoing fundamental changes. Earlier this year, the BBC confirmed that the show was put out to competitive tendering, a process designed to select the future producer of the series. Although the BBC will maintain ownership of all rights to the program, this competitive process is set to alter the foundational elements of the series. The show, which was not originally conceived as a soap or a continuing drama, is embracing a "reimagining". According to Will Beck, these parameters are "really exciting and I think unprecedented," representing a look toward the next 40 years of the show. Holby to Wales: The Historic Casualty Relocation The most significant change resulting from this tendering process is the relocation of the drama’s setting. Once the new production company takes over, the ED will no longer be set in the fictional city of Holby. Instead, the location of the Emergency Department will be set in Wales . The BBC document related to the tender explicitly requested that the successful bidder include an authentic representation of Wales and reflect the reality of the Welsh NHS. This shift mandates a "new fictional hospital based in Wales". The move is viewed as a massive opportunity, providing at least three years for the creative team to demonstrate that Wales is a place that "offers drama". While this represents a core change, the broadcaster has indicated that while the relocation offers opportunities for new cast members, beloved characters are expected to remain part of the editorial shift to the new Welsh location. Image credit: BBC / Casualty . Fair use. Beyond Ngozi: Unresolved Relationships and Lingering Threats The conclusion of the Supply and Demand  chapter left several other complex personal and professional conflicts hanging. One of the most immediate unresolved threads involves Faith Cadogan and Iain Dean. The boxset finale saw paramedic Iain deliver a shocking revelation to Faith, telling her he didn't love her and only wanted to "save" her, leaving his advanced clinical practitioner wife heartbroken. The complexities of their relationship have been developing for some time; earlier in the year, Faith was on the verge of relapsing, and later, the couple wrestled with whether their wedding would even proceed. Iain's confession casts a major shadow over their future, creating tension that will undoubtedly follow them into the new series. The broader drug crisis storyline, which permeated much of Supply and Demand , also created significant repercussions for many staff members. Rash Masum (Neet Mohan) found his relationship with pharmacist Sunny Callahan jeopardized after her actions led to a brutal attack. Nurse Rida Amaan (Sarah Seggari) faced harrowing situations, including being subjected to a shocking attack while trying to gather evidence against predatory surgeon Russell Whitelaw, forcing her to confront abhorrent misconduct and fight against pressure to remain silent. These heavy storylines demonstrate the depth of emotional and professional conflict awaiting resolution when the show returns. A Focus on Character and Crisis Beyond the immediate crisis facing Ngozi, the show's previous installments highlighted intense personal pressures among the staff. Trainee paramedic Indie Jankowski (Naomi Wakszlak) faced multiple challenges, including homelessness and making a career-ending mistake, before receiving a lifeline. Furthermore, clinical lead Flynn Byron (Olly Rix), who arrived disrupting the status quo, had to face his own trauma and resolve to turn things around with the help of Dylan Keogh. This continuous focus on character arcs and professional dilemmas ensures the Casualty  brand of emergency drama remains intense. The next mini-series, Learning Curve , must address not only the medical emergency surrounding Ngozi but also the broken relationships, lingering guilt, and ethical challenges that closed out the previous chapter. With the backdrop of the impending Casualty Relocation to Wales , the upcoming episodes are set to provide both closure and a dramatic new beginning. 🔖 Key Takeaways 🗝️ Delayed Return Date:  The official Casualty Return Date  is January 10 . It was previously slated for the end of 2025 but was postponed until after the Christmas and New Year viewing period. 🗝️ Ngozi Okoye’s Fate:  The Supply and Demand  boxset ended with Ngozi Okoye being rushed to the ED after relapsing, collapsing, and hitting her head at the airport. The next mini-series, Learning Curve , will reveal if she survived. 🗝️ Dylan Keogh’s Role:  Dylan Keogh, Ngozi’s sponsor, will be central to the drama, struggling with the aftermath if Ngozi dies and wanting to investigate what transpired. 🗝️ Major Relocation:  The BBC is changing the show's foundations through competitive tendering. The ED will be removed from the fictional city of Holby and relocated to a setting in Wales , requiring the show to authentically reflect the Welsh NHS. 🗝️ Unresolved Drama:  Key storylines left unresolved include Iain Dean’s revelation to Faith Cadogan that he doesn't love her, the fallout from the drug crisis, and Rida Amaan's difficult battle against misconduct. 🌐 External sources Casualty return date confirmed – and it’s bad news for fans When is Casualty next on? Our guide to every episode of BBC’s medical drama in 2025 When will Casualty return?

Image credit: ABC / The Dropout . Fair use. The narrative surrounding Elizabeth Holmes and her health technology company, Theranos, is a quintessential modern cautionary tale of ambition colliding with reality in Silicon Valley. Holmes, who dropped out of Stanford before her sophomore year, used her tuition money to fund research for Theranos. She promised a potentially revolutionary piece of technology—a device, known as the Edison, that could perform dozens of health tests using just a single drop of blood from a finger prick, rather than needing a needle in a vein. This promise captivated investors, helping Theranos achieve a valuation of $9 billion (£7bn) at its peak. Holmes cultivated a public image often compared to the late Apple co-founder Steve Jobs, spinning a powerful narrative of fast, accessible, and affordable healthcare. Her public message, such as her statement at TEDMED 2014, suggested a world where people wouldn't have to say, "If only I’d known sooner". However, this almost utopian vision was destined never to materialize. The core problem was brutally simple: the technology did not work as advertised, ultimately being deemed "nothing more than a mirage" built on "half-truths and outright lies". Content ⁉️ 1️⃣ Unmasking the Deception: The Theranos Downfall 2️⃣ The Road to Conviction and Sentencing 3️⃣ Elizabeth Holmes Fraud Appeal Rejected 4️⃣ Financial Consequences: Restitution Upheld 🔖 Key Takeaways Image credit: CNBC / The Dropout . Fair use. Unmasking the Deception: The Theranos Downfall The Theranos Downfall  began in earnest in late 2015 when internal struggles and the severe limitations of the company’s technology were exposed by investigative news reporting. Reporter John Carreyrou led a damning investigation for the Wall Street Journal , which was significantly aided by whistleblowers, including former Theranos research engineer Tyler Shultz. The Edison Machine’s Fatal Flaw Carreyrou’s initial report revealed that the supposedly revolutionary Edison machine was not capable of running the volume of tests Theranos claimed. In fact, the company was sometimes forced to utilize machines from rival companies instead. Beyond the technological limitations, the reliability of the proprietary technology was highly questionable. The consequences of this failure were severe, involving real patient harm, including cases where a pregnant woman received results wrongly indicating a miscarriage, and another individual received a false-positive HIV test. Another whistleblower, Erika Cheung, testified that the results produced by the Edison were roughly as accurate as tossing a coin. The Wall Street Journal coverage generated intense scrutiny and mounting pressure on the company. This ultimately triggered an investigation by the Securities and Exchange Commission (SEC), which later stated that innovators "must tell investors the truth about what their technology can do today – not just what they hope it might do someday". Image credit: Forbes / The Dropout . Fair use. The Road to Conviction and Sentencing Following the public revelations and a two-and-a-half-year investigation, a grand jury indicted Holmes and her ex-business and romantic partner, Ramesh "Sunny" Balwani. Balwani served as an executive at Theranos and was Holmes' mentor and former lover for over a decade. Holmes' trial, delayed by her pregnancy and the COVID-19 pandemic, finally commenced in September 2021. In January 2022, she was convicted of conspiracy and multiple charges of wire fraud for misleading investors regarding the company's financial health and the effectiveness of its proprietary technology. Holmes was found not guilty on four counts of defrauding patients. In November 2022, she was sentenced to 11 years and three months in prison. Balwani, tried separately, was convicted on all counts, including two counts of conspiring with Holmes, six counts of defrauding investors, and four counts of patient fraud, receiving a sentence of 12 years and 11 months. Holmes began serving her sentence at a federal prison in Bryan, Texas, in May 2023. Elizabeth Holmes Fraud Appeal Rejected In early 2025, Holmes lost her appeal against her conviction for defrauding investors. The Ninth Circuit Court of Appeals decisively rejected the arguments presented by Holmes. Judge Jacqueline H Nguyen wrote in the opinion that the claims Theranos made about running blood tests using a finger prick were "nothing more than a mirage" and that the achievements touted by Holmes and Balwani were based on "half-truths and outright lies". Arguments Dismissed In her appeal, Holmes challenged several aspects of the trial, including specific evidence and testimony. She argued that statements made by Balwani, where he claimed he "owned" the company’s financial model, should have been included in her trial. Furthermore, the appeal argued that the testimony offered by former Theranos employees constituted improper expert testimony, and that a government inspection report should not have been admitted as evidence. The court dismissed all these arguments. Balwani also challenged his conviction and lost his appeal. In May 2025, Holmes lost a subsequent bid to have her appeal reheard by the original three-judge panel that upheld her conviction. Since no judge on the circuit court asked for a vote on a full court rehearing, the Supreme Court remains Holmes’ last judicial avenue to overturn her conviction. Image credit: BLOOMBERG / The Dropout . Fair use. Financial Consequences: Restitution Upheld Beyond the prison sentences for Elizabeth Holmes Fraud , both Holmes and Balwani were ordered to pay a massive sum in restitution to their victims. The court upheld the order for them to pay $452 million (£358m) in restitution . The trajectory of Holmes’ life, which saw her go from being Forbes' "youngest self-made female billionaire" to a convicted fraudster, has been widely documented, including through the drama miniseries The Dropout , which aired on BBC One and Disney Plus. The series dramatized certain elements, particularly the relationship between Holmes and Balwani, due to limited public information. However, the core events of the Theranos Downfall  remain true, serving as a powerful lesson for innovators about the absolute necessity of transparency and truth in the face of immense financial pressures. 🔖 Key Takeaways The final legal decisions confirm the gravity of the Elizabeth Holmes Fraud  and the Theranos Downfall . 🗝️ Conviction Upheld:  The Ninth Circuit Court of Appeals affirmed Holmes' 2022 conviction for wire fraud and conspiracy for misleading investors, emphasizing that the technology promised by Theranos was fraudulent. Holmes has now exhausted her options at the circuit level. 🗝️ Restitution:  Both Holmes and Balwani were legally ordered to pay $452 million in restitution to victims, an order upheld by the court. 🗝️ The Deception:  The company's core technology, the Edison machine, failed to deliver on its promise of providing dozens of accurate tests from a single blood drop, relying instead on conventional machines and producing highly unreliable results. 🗝️ Co-conspirator:  Ramesh "Sunny" Balwani, Holmes' ex-partner and business executive, also lost his appeal and remains convicted and sentenced for his role, including patient fraud charges that Holmes was acquitted of. 🌐 External sources The Dropout true story: Elizabeth Holmes scandal explained Theranos founder Elizabeth Holmes loses fraud appeal Theranos founder Elizabeth Holmes loses bid to have appeal of fraud conviction reheard